catalyst hypogen (Hypogen Inc)
90
Structured Review
Hypogen Inc
catalyst hypogen
Catalyst Hypogen, supplied by Hypogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studios+catalyst+hypogen+algorithm/catalyst+hypogen/pmc09042709-157-9-10
Average 90 stars, based on 1 article reviews
Catalyst Hypogen, supplied by Hypogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/discovery+studios+catalyst+hypogen+algorithm/catalyst+hypogen/pmc09042709-157-9-10
Average 90 stars, based on 1 article reviews
catalyst hypogen - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: The Use of Methods of Computer-Aided Drug Discovery in the Development of Topoisomerase II Inhibitors: Applications and Future Directions. Article Snippet: Subscriber access provided by University of Birmingham is published by the American Chemical Society.. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society.. Copyright © American Chemical Society. Article Title: Identification of 3-((1-(Benzyl(2-hydroxy-2-phenylethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamoyl)pyrazine-2-carboxylic Acid as a Potential Inhibitor of Non-Nucleosidase Reverse Transcriptase Inhibitors through InSilico Ligand- and Structure-Based Approaches Article Snippet: The ligand-based drug design can possibly be performedwith the software programs such asSYBYL/comparative molecular field analysis (CoMFA) [ ], comparative molecular similarity indices analysis (CoMSIA) [ ], and Article Title: Computational Modeling of Drugs Against Alzheimer’s Disease Article Snippet: The design of new Article Title: Exploration of Mycobacterium tuberculosis structural proteome: An in-silico approach. Article Snippet: Pharmacophore approaches are of central contour in drug discovery.. However, the dependence of ligand–based pharmacophore model on appropriate training set molecules and typical use of apo– protein or single protein–ligand complex for the construction of structure–based pharmacophore models might skip some vital information.. Therefore, multiple–complex based approach was employed for the construction of pharmacophore models of the Mycobacterium structural proteome. Article Title: Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors. Article Snippet: The P-glycoprotein (P-gp) efflux pump has an important role as a natural detoxification system in many types of normal and cancer cells.. P-gp is implicated in multiple drug resistance (MDR) exhibited by several types of cancer against a multitude of anticancer chemotherapeutic agents, and therefore, it is clinically validated target for cancer therapy.. Accordingly, in this study we combined exhaustive pharmacophore modeling and quantitative structure-activity relationship (QSAR) analysis to explore the structural requirements for potent P-gp inhibitors employing 130 known P-gp ligands. Article Title: Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents Article Snippet: To discover novel PI3Kγ inhibitors as anticancer agent, Taha et al [ ] explored the pharmacophoric space of PI3Kγ via diverse inhibitors and used Article Title: Pharmacophore modeling, docking and the integrated use of a ligand- and structure-based virtual screening approach for novel DNA gyrase inhibitors: synthetic and biological evaluation studies Article Snippet: This may be achieved by using software such as Article Title: Discovery of new Cdc2-like kinase 4 (CLK4) inhibitors via pharmacophore exploration combined with flexible docking-based ligand/receptor contact fingerprints and machine learning Article Snippet: Table S4 under ESI shows information about representative pharmacophores including their features, success criteria, differences from corresponding null hypothesis and |